Idemoto Keita, Niitsu Tomihisa, Hata Tatsuki, Ishima Tamaki, Yoshida Sumiko, Hattori Kotaro, Horai Tadasu, Otsuka Ikuo, Yamamori Hidenaga, Toda Shigenobu, Kameno Yosuke, Ota Kiyomitsu, Oda Yasunori, Kimura Atsushi, Hashimoto Tasuku, Mori Norio, Kikuchi Mitsuru, Minabe Yoshio, Hashimoto Ryota, Hishimoto Akitoyo, Nakagome Kazuyuki, Hashimoto Kenji, Iyo Masaomi
Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.
Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.
Psychiatry Res. 2021 Jul;301:113967. doi: 10.1016/j.psychres.2021.113967. Epub 2021 Apr 27.
Glial cell line-derived neurotrophic factor (GDNF) plays an important role in the pathophysiology of neuropsychiatric disorders. We examined serum GDNF levels in bipolar disorder (BD) patients and major depressive disorder (MDD) patients and their association with response to lithium therapy. We used a multicenter (six sites), exploratory, cross-sectional case-control design and recruited 448 subjects: 143 BD patients, 116 MDD patients, and 158 healthy controls (HCs). We evaluated the patients' clinical severity using the Clinical Global Impression (CGI), and responses to lithium therapy using the Alda scale. The serum GDNF levels were significantly decreased in the BD and MDD groups compared to the HCs, with no significant difference between the BD and MDD groups. After adjustment, the serum GDNF levels in the BD and MDD patients in remission or depressive states were decreased compared to the HC values. Lower serum GDNF levels in BD patients were associated with higher CGI and Alda scores (i.e., severe illness and good response to lithium therapy, respectively). Our findings suggest that the serum GDNF level may be a biomarker for both BD and MDD in remission or depressive states. The serum GDNF level may be associated with the lithium response of BD patients.
胶质细胞源性神经营养因子（GDNF）在神经精神疾病的病理生理学中起着重要作用。我们检测了双相情感障碍（BD）患者和重度抑郁症（MDD）患者的血清GDNF水平，以及它们与锂盐治疗反应的相关性。我们采用多中心（六个地点）、探索性、横断面病例对照设计，招募了448名受试者：143名BD患者、116名MDD患者和158名健康对照（HC）。我们使用临床总体印象量表（CGI）评估患者的临床严重程度，并使用阿尔达量表评估对锂盐治疗的反应。与HC相比，BD组和MDD组的血清GDNF水平显著降低，BD组和MDD组之间无显著差异。调整后，缓解期或抑郁状态的BD和MDD患者的血清GDNF水平低于HC值。BD患者较低的血清GDNF水平与较高的CGI和阿尔达评分相关（分别表示疾病严重和对锂盐治疗反应良好）。我们的研究结果表明，血清GDNF水平可能是缓解期或抑郁状态下BD和MDD的生物标志物。血清GDNF水平可能与BD患者的锂盐反应有关。
